News Channels

15 May 2023 BiOneCure Therapeutics and Nanjing Leads Biolabs Join Forces to Develop Innovative Anti-Drug Conjugates (ADCs) for Solid Tumor Treatment
15 May 2023 AnHorn Medicines Presents Research of Novel Protein Degrader for Topical Use at ISID Meeting 2023
15 May 2023 U.S. Food and Drug Administration Issues Complete Response Letter for Byondis' [Vic-]Trastuzumab Duocarmazine
15 May 2023 Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
15 May 2023 Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis English
15 May 2023 Acesion Pharma Announces Positive Pre-Clinical Data for AP31969
15 May 2023 Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program
13 May 2023 GSK presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains
13 May 2023 Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113
13 May 2023 LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
13 May 2023 Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause
12 May 2023 Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
11 May 2023 Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586
11 May 2023 Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023
11 May 2023 Extend Biosciences Announces Positive Data from Phase 1 Trial of EXT608 for the Treatment of Hypoparathyroidism
11 May 2023 CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrome in Oncology
11 May 2023 Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
10 May 2023 Codagenix Initiates Dosing in Phase 1 Study of Intranasal, Live-Attenuated RSV
10 May 2023 Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)
10 May 2023 Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up